Unique ID issued by UMIN | UMIN000018544 |
---|---|
Receipt number | R000021461 |
Scientific Title | A prospective observational study for impact on patient's quality of life associated risk factor of chemotherapy induced nausea and vomiting in highly emetogenous chemotherapy |
Date of disclosure of the study information | 2015/08/05 |
Last modified on | 2018/02/06 10:57:09 |
A prospective observational study for
impact on patient's quality of life associated risk factor of chemotherapy induced nausea and vomiting in highly emetogenous chemotherapy
A prospective observational study for
impact on patient's quality of life associated risk factor of chemotherapy induced nausea and vomiting in highly emetogenous chemotherapy
A prospective observational study for
impact on patient's quality of life associated risk factor of chemotherapy induced nausea and vomiting in highly emetogenous chemotherapy
A prospective observational study for
impact on patient's quality of life associated risk factor of chemotherapy induced nausea and vomiting in highly emetogenous chemotherapy
Japan |
cancer
Breast surgery |
Malignancy
NO
We evaluate impact on patient's quality of life associated risk factor of chemotherapy induced nausea and vomiting in highly emetogenous chemotherapy.
Others
To evaluate impact on patient's quality of life associated risk factor of chemotherapy induced nausea and vomiting in highly emetogenous chemotherapy
Exploratory
Pragmatic
Not applicable
Rate of no impact on patient's QOL during 0 to 120 hours (all phase) after an anticancer agent dosage start
1) Rate of no impact on patient's QOL during 0 to 24 hours (acute phase) after an anticancer agent dosage start
2) Rate of no impact on patient's QOL during 24 to 120 hours (delay phase) after an anticancer agent dosage start
3) Complete protection rate during 0 to 24 hours (acute phase) after an anticancer agent dosage start
4) Complete protection rate during 24 to 120 hours (delay phase) after an anticancer agent dosage start
Observational
20 | years-old | <= |
Not applicable |
Male and Female
1) The patient who plans anticancer agent of high emetic risk
2) The patient whom an anticancer agent is not given to anticancer agent of high emetic risk in the past
3) The planned patient who gives antiemetic drugs including aprepitant or fosaprepitant and palonosetron
4) Age at the time registration is a patient 20 years or older
5) The patient who did not experience nausea and vomiting within 24 hours before giving an anticancer agent
6) Given written informed consent
1) Any other inadequacy for this study
2) Presence of brain metastases
3) Hypercalcemia
4) Gastrointestinal obstruction
5) other medication or participation in studies that might modify the usual chemotherapy induced nausea and vomiting pattern or the emetogenous level of the chemotherapy regimen received
100
1st name | |
Middle name | |
Last name | Kazutaka Narui |
Yokohama City University Medical Center
Department of Breast and Thyroid Surgery
4-57 Urahunecho, Minami-ku, Yokohama City, 232-0024, Japan
045-261-5656
nr1@gc5.so-net.ne.jp
1st name | |
Middle name | |
Last name | Jumpei Tokumaru |
Yokohama City University Medical Center
Pharmaceutical Department
4-57 Urahunecho, Minami-ku, Yokohama City, 232-0024, Japan
045-261-5656
toku_j@yokohama-cu.ac.jp
Yokohama City University Medical Center
None
Self funding
NO
2015 | Year | 08 | Month | 05 | Day |
Published
Main results already published
2014 | Year | 05 | Month | 30 | Day |
2014 | Year | 05 | Month | 30 | Day |
2017 | Year | 12 | Month | 31 | Day |
2017 | Year | 12 | Month | 31 | Day |
2017 | Year | 12 | Month | 31 | Day |
2017 | Year | 12 | Month | 31 | Day |
We evaluate impact on patient's quality of life associated risk factor of chemotherapy induced nausea and vomiting in highly emetogenous chemotherapy.
2015 | Year | 08 | Month | 05 | Day |
2018 | Year | 02 | Month | 06 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000021461